TO THE EDITOR Molecular analysis of the Philadelphia (Ph) chromosome has shown that the 3Ј sequences of the tyrosine kinase c-ABL proto-oncogene (located on chromosome 9q34) and the 5Ј sequences of the BCR gene (located on chromosome 22q11) are joined in the Ph translocation. The various breakpoints on the two chromosomes give different fusion transcripts with different BCR-ABL junctions. Most chronic myeloid leukemia (CML) patients with Ph chromosome express the BCR-ABL transcript with the most frequent junctions b3a2 (e14a2) or b2a2 (e13a2) corresponding to the BCR gene breakpoints located in a central region called the 'major breakpoint cluster region' (M-bcr). On the other hand, a shortened BCR-ABL transcript with an e1a2 type of junction (m-bcr or 'minor breakpoint cluster region' on the BCR gene) is frequently expressed in patients with Ph-positive acute lymphoid leukemia (ALL). Only sporadic cases express the other junctions; e19a2, b2a3 or b3a3. 1, 2 We have studied the case of a CML patient with a Ph chromosome expressing the rare e6a2 junction of the BCR-ABL fusion gene.
This patient, a 50-year-old man, was referred to our center in 1999 with a high white blood cell (WBC) count. He had in 1990, a medical history of idiopathic thrombocytopenic purpura (ITP), which required a splenectomy to be cured. The first blood count showed 63.6×10 9 /1 WBC with 1% blast cells, 227 × 10 9 /1 platelets and 12.4 g/dl hemoglobin. The bone marrow was hypercellular with a granulocytic predominance. The patient was treated according to arm A of a randomized trial of the French Bone Marrow Transplantation Society, which compared initial unpurged autologous peripheral blood stem cell transplantation followed by interferon-␣ plus cytarabine (arm A) to standard treatment with interferon-␣ plus cytarabine (arm B).
Chromosome preparations were made with standard techniques from bone marrow at presentation. Metaphase chromosomes were Giemsa reverse banded and karyotyped according to the International System for Human Cytogenetic Nomenclature (ICSN). The LSI BCR-ABL translocation probes (Vysis, USA) were hybridized in situ to metaphase chromosomes obtained from bone marrow culture using a method described previously. 3 The LSI BCR-ABL translocation probe is a mixture of a probe for the BCR locus (between exon 13 and 14 towards the centromere on chromosome 22, approximately 300 kb) and a probe for the ABL locus (between exon 4 and 5 towards the telomere of chromosome 9, approximately 200 kb).
After conventional RNA extraction 4 and cDNA synthesis by Moloney's murine leukemia virus (MMLV) RTase (Life Technologies, France), amplification was performed with three l of cDNA in PCR mix containing Ampli Taq Gold (Perkin Elmer, France) and 0.15 m of each primer for specific transcripts. After electrophoresis, hybridization was performed with a biotinylated end-labeled oligonucleotide using standard methods. Negative (without RTase), positive (with K562 erythroleukemic cell line or patient with ela2 junction) and water controls were used in all tests. RNA quality was controlled by RT-PCR amplification of the ubiquitously expressed ABL transcript with primers in exons a2 and a3. 5 Oligonucleotide primers used in our multiplex BCR-ABL mix to detect common transcript types were: ABL-a3-b, BCR-el-c and BCR-b2-c as described in the BIOMED-1 Concerted Action. 6 Bands of 377 bp, 302 bp or 398 bp were obtained respectively for b3a2, b2a2 or ela2 junctions. To eliminate false negative results, we used a moderately expressed housekeeping gene, the hypoxanthine phosphoribosyltransferase gene (HPRT), as internal PCR control. 7 HPRT primers (0.075 m) were integrated in the multiplex BCR-ABL mix to obtain a fragment of 213 bp. Primers used for the e6a2 junction were: ABL-a3-b 6 and a new BCR primer, E6A (in exon 6); 5Ј AAAGATGCCAAGGATCCAACG, nucleotide number 105631 for 5Ј position (accession number U07000). Direct sequencing of PCR products for the e6a2 junction was performed by big-dye terminator methodology (Perkin-Elmer, Courtaboeuf, France). Products were analyzed on an ABI 310 and treated by Genescan software (Perkin-Elmer).
Using the standard cytogenetic analysis first, we showed the presence of an apparently classic Ph chromosome. No normal metaphases were present. The karyotype of the abnormal clone was therefore interpreted as 46, XY, t(9;22)(q34;q11). By in situ hybridization analysis on metaphases we observed a fluorescent signal that indicated the fusion of the BCR and ABL oncogenes on Ph chromosome (not shown). At diagnosis, the initial screening with the BCR-ABL mix showed the normal HPRT fragment and an atypical large amplification product (over 1000 bp) of weak intensity (data not shown). This PCR product hybridized well with the specific biotinylated ABL-a3-d probe. 6 Then the specific single-tube PCR using ABL-a3-b and E6A primers produced a 272 bp amplification product (Figure 1 ). Hybridization with the ABL-a3-d probe confirmed the specificity of the BCR-ABL amplification product. PCR products were sequenced with each primer and the results showed a corresponding fusion between exon e6 of the BCR gene and exon a2 of the ABL gene, resulting in an e6a2 BCR-ABL transcript (Figure 1b) . Serial 10-fold step dilutions of leukemic RNA from bone marrow at diagnosis with RNA of normal cells (RNA in RNA) demonstrated a RT-PCR sensitivity of 10 −5 ( Figure  1c ). Using this sensitive RT-PCR method, residual leukemic cells could be detected in bone marrow before and after graft.
Two cytogenetic methods, ie a standard technique and in situ hybridization have indicated the presence of the Ph translocation in our CML patient and the fusion of BCR and ABL oncogenes was shown with the selected probes. Generally, using our multiplex PCR strategy, we were able to detect common transcripts and for the first time we identified an atypical BCR-ABL transcript. Cross et al 8 have already presented an optimized multiplex PCR for detection of BCR-ABL transcripts. All possible BCR-ABL variants should be detected by these routine PCR strategies and, moreover, the absence of nested PCR in our method minimized the risk of contamination.
In view of the large amplification product obtained, we predicted that the junction on the BCR gene could occur in a downstream exon. As shown by Hochhaus et al, 9 we suspected the presence of the rare e6a2 junction of a BCR-ABL transcript. This hypothesis was confirmed by PCR amplification with the new E6A primer and sequencing. These last results were in agreement with in situ hybridization analysis since the BCR probe used in our study was able to cross beyond the M-bcr and m-bcr regions (exons 1 to 13) and therefore the exon 6 region. While Hochhaus et al had found an e6a2 BCR-ABL fusion gene in a CML patient with Ph-negative chromosome according to the cytogenetic definition, we present a CML patient with Ph-positive chromosome and the rare e6a2 junction. −5 was confirmed after hybridization with a specific ABL-a3-d probe (lower illustration). M, biotinylated molecular weight marker; 1000, 700, 500, 400, 300, 200 bp from top to bottom. On the right, PCR product was detected in bone marrow before and after graft.
